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Introduction: Non coeliac gluten sensitivity (NCGS) is an emerging clinical entity with a prevalence of 0.5-13%. It is
characterised by gluten related symptoms with a negative coeliac serology and no villous atrophy (VA). It is currently a
diagnosis based on exclusion of coeliac disease (CD). We aimed to assess the role of Simtomax, an IgA/G deamidated
gliadin peptide (DGP) based point of care test (POCT), in differentiating between NCGS and CD. 
Methods: Group 1: we compared the sensitivities of 3 POCTs: Simtomax, Biocard [IgA-tissue transglutaminase (TTG)]
and Celiac Quick Test (IgA/G/M-TTG). We prospectively recruited 100 patients referred with a positive endomysial
antibody (EMA) attending for a gastroscopy. All patients undertook the 3 POCTs, EMA, TTG, and all underwent a
gastroscopy with 5 duodenal biopsies. Sensitivities were measured based on their histology.
Group 2: the sensitivity of Simtomax in the general population was evaluated by prospectively recruiting 667 patients with
gastrointestinal  symptoms  or  ataxia  attending  for  a  gastroscopy.  To  reduce  positive  ascertainment  bias,  we  excluded
patients referred with a positive EMA, previous VA, known CD, self-reported gluten sensitivity, and those on a gluten free
diet.  All  patients  undertook  Simtomax,  EMA,  TTG  and  a  gastroscopy  with  5  duodenal  biopsies.  Sensitivities  were
measured based on their histology.
Group  3:  we  demonstrated  the  sensitivities  of  Simtomax  in  a  gluten  sensitive  population.  35  patients  with  self-reported
gluten sensitivity  attending for  a  gastroscopy were prospectively  recruited.  All  patients  undertook Simtomax,  EMA, TTG
and a gastroscopy with 5 duodenal biopsies. Sensitivities were measured based on their histology. 
Results: Group 1 showed that Simtomax was the best POCT in detecting CD. The CD prevalence was 85%. In group 2,
the sensitivity and negative predictive value (NPV) of Simtomax were comparable to that of EMA and TTG. The
prevalence of CD was 4.95%. In group 3, Simtomax had 100% sensitivity and NPV in differentiating between CD and
NCGS. 4 patients (11.4%) were diagnosed with CD, 4 (11.4%) with potential CD (positive serology but no VA) and 27
(77.1%) with NCGS (negative serology and no VA). 
Gp 1 Sensitivity, % Specificity, % PPV, % NPV, %
Simtomax 96.5 6.67 85.4 25
Biocard 71.8 53.3 89.7 25.0











EMA 72.7 99.5 88.9 98.6











EMA 75.0 96.8 75.0 96.8
TTG 75.0 87.1 42.9 96.4
Conclusion: Simtomax was the most accurate POCT for detecting CD. In a lower CD prevalence group 2 cohort, its
sensitivity remained comparable to TTG and EMA. Simtomax had 100% sensitivity in detecting CD in patients with self-
reported gluten sensitivity, and 100% NPV in identifying patients with NCGS. 
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